Efficacy and Safety of Percutaneous Transluminal Septal Myocardial Ablation Treating Hypertrophic Cardiomyopathy: Systematic Review and Meta‐Analysis

Background: Percutaneous transluminal septal myocardial ablation (PTSMA) is one of the invasive therapeutic measures for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM). Objective: To systematically evaluate the efficacy and safety of PTSMA in patients with HCM. Methods: A systematic searching of Pubmed, Web of Science, Embase, and Cochrane Library databases was conducted for screening of studies conducted from library building to October 20, 2024 involving the treatment of PTSMA in patients with HCM. Two investigators independently screened the literature, extracted the data, and evaluated the risk of bias in the included study; meta‐analysis was performed using Stata14.0 software. Results: A total of 10 literature articles were included. The mean LVOT PG reduction of 1910 patients with HCM after PTSMA treatment was 47.74 mmHg (95% CI: 39.75–55.72, p < 0.01). The mean reduction in the maximum septal thickness was 4.76 mm (95% CI: 3.67–5.85, p < 0.01). The incidence of the central package effusion in surgical complications was 2% (95% CI: 0%–3%, p < 0.01). The incidence of the left bundle branch block was 19% (95% CI: 5%–39%, p < 0.01).The incidence of right bundle branch block was 9% (95% CI: 4%–17%, p < 0.01). The incidence of the all‐cause death from follow‐up events was 2% (95% CI: 0%–5%, p = 0.01). The incidence of pacemaker implantation was 6% (95% CI: 4%–10%, p < 0.01). Conclusion: PTSMA is effective and safe in treating patients with HCM.